Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…